Is Tilray’s Growth Enough for Investors?

By Chris Lange Updated Jan 30, 1:15PM EST · Published Nov 12, 4:22PM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Is Tilray’s Growth Enough for Investors? — © van_mij / Flickr

Tilray Inc. (NASDAQ: TLRY) released third-quarter financial results after the closing bell on Tuesday. The company said that it had a net loss of $0.50 per share and $51.1 million in revenue, compared with consensus estimates that called for a net loss of $0.29 per share and $49.41 million in revenue. The same period from last year had a net loss of $0.20 per share and $10.05 million in revenue.

Overall, revenues increased 408.6% year over year, driven by the Canadian adult-use market, the Manitoba Harvest acquisition, and growth in international medical markets as a result of the first GMP certification of the Portugal facility.

Total kilogram equivalents sold increased over six-fold to 10,848 kilograms from 1,613 kilograms in the prior-year period.

The average net selling price per gram decreased to $3.25 compared to $6.21 in the prior-year period. The average net selling price excluding excise taxes for adult-use was $2.98 per gram for the third quarter of 2019. The decrease was due to a shift in product and channel mix.

[nativounit]

Brendan Kennedy, Tilray’s president and CEO, commented:

Our performance in the third quarter, including solid revenue growth and sequential gross margin expansion, reflects the positive business trends we have underway. We are in the early days of seeing our strategic initiatives bear fruit – including our European expansion, brand portfolio evolution and strategic partnership product launches. We continue to expect significant growth in the fourth quarter and into 2020.

Shares of Tilray closed Tuesday at $21.57, with a 52-week range of $20.20 to $120.40. The consensus analyst price target is $37.00. Following the announcement, the stock was initially up 2% at $22.00 in the after-hours session.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.